FDA approves tovorafenib for most common form of childhood brain tumor
Key takeaways: FDA approves Tovorafenib (Ojemda) for pediatric low-grade glioma (LGG) with BRAF mutations, marking the first systemic therapy for this condition. Approval based on FIREFLY-1 trial showing 51% overall response rate (ORR) and median response …